GBI Research, Dec 2009, Pages: 198
and the steady increase in incidence rates of CNS complications. This market is expected to grow to $121 billion with a CAGR of 2.8% by year 2015. The authors examined the CNS markets in US, EU5 (includes UK
John Wiley and Sons Ltd, April 2010, Pages: 272
in patient populations are also discussed.
Written by a team of clinical scientists involved in CNS drug trials for over 20 years, and based on a wealth of drug development and clinical trial experience
Venture Planning Group, Sep 2011
Global CNS Drug Market: Strategic Assessments of Leading Suppliers This report provides industry executives with strategically significant competitor information and analysis of the leading players
Medpredict, May 2010, Pages: 143
NOT put on their fantasy formularies. This is the second year we’ve conducted this exercise and we provide both years’ results for comparison. The other aims of this Panel were to review progress
John Wiley and Sons Ltd, Jan 2011, Pages: 252
The Year in Diabetes and Obesity The Year in Diabetes and Obesity will fulfill a critical need by publishing timely, thought-provoking reviews on the molecular, basic, and clinical aspects
Jain PharmaBiotech, May 2012, Pages: 754
and the share of this market by new technologies and state of development at any given year in the future. This is based on a comprehensive and thorough review of the current status of nanobiotechnology
Jain PharmaBiotech, May 2012, Pages: 1015
and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.
The number of companies involved in cell therapy has increased remarkably during the past few years
Venture Planning Group, Sep 2011
, and others.
In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including
Global Industry Analysts, Inc., April 2011, Pages: 1088
Markets
Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 106
Table 19: World Historic Review for Pediatric CNS Drugs
Espicom Business Intelligence Ltd, Jan 2010, Pages: 84
intends to focus its product base on CNS diseases and the treatment of diabetes and associated complications.
This pharmaceutical company intelligence report provides a full review of the company
Jain PharmaBiotech, May 2012, Pages: 530
collaborations. These are a mix of pharmaceutical companies and biotechnology companies.
The worldwide analgesic markets were analyzed for the year 2011 and projected to 2021. Calculations are based
GlobalData, Dec 2009, Pages: 46
, forecast forward for 7 years to 2015.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different
GlobalData, Dec 2009, Pages: 53
experts.
Scope
The scope of the report includes:
- Annualized global bipolar disorder market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
- Geographies covered in this report
John Wiley and Sons Ltd, March 2011, Pages: 252
The Year in Human and Medical Genetics The latest edition of The Year in Human and Medical Genetics explores new trends in Mendelian genetics. While Mendelian genetics is often seen as an out-dated
Business Insights, July 2011, Pages: 97
Opportunities and Key Players in Medical Nutrition A small number of products for specific diseases have been introduced over the years, but companies have only recently started to focus
Venture Planning Group, Sep 2011
, ophthalmic, and others.
In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years
Espicom Business Intelligence Ltd, June 2010, Pages: 70
Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results
GBI Research, Feb 2010, Pages: 85
. It also reviews the factors determining the success and failure of the strategies providing an understanding of how to ensure success for LCM.
This report is built using data and information sourced from
